🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Comparison of Alpha Blockers (Terazosin and Tamsulosin) in Reducing Ureteral Stent Related Symptoms

RecruitingPhase 3Ages 18 Years - anyAllPenang Hospital, Malaysia
NCT06966804 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The goal of this clinical trial is to compare how well Terazosin, Tamsulosin and standard care (no alpha-blocker) reduce urinary symptoms after ureteral stent placement. This trial also learn about the safety of these two study medications. Main objective: • To compare how well Terazosin, Tamsulosin and standard of care reduce post-stenting urinary symptoms. Secondary objectives: * To assess differences in Body pain, General health, Work performance, Sexual matters, and Additional problems using a questionnaire (USSQ). * To assess differences in side effects. After stent placement, subjects will be randomly assigned to one of three groups: 1. Terazosin (alpha-blocker) for 14 days 2. Tamsulosin (alpha-blocker) for 14 days 3. Standard of care (no alpha-blocker). All subjects will be discharged with standard pain-killers and a diary to track usage. Subjects in Terazosin and Tamsulosin

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Malaysian age 18 years old and above. 2. Able to provide written informed consent to participate in the trial. 3. Willing to comply with study procedures. 4. Unilateral intracorporeal lithotripsy procedure with ureteral stent placement for uncomplicated ureteric or renal calculi Exclusion Criteria: 1. Known comorbidity that increase the risk of complication 1. Prostate pathology: Benign prostate hyperplasia, prostatitis, prostatic carcinoma 2. Bladder pathology: Bladder tumor, stone, overactive bladder 3. Ureteral abnormality/ trauma, urethral stricture 4. Concomitant urinary tract infection 5. Orthostatic hypotension 6. Solitary kidney 2. Previous pelvic/ gynaecological surgery 3. Patient is concomitantly receiving treatment from a pain clinic for chronic pain management. 4. Pregnancy (for women of childbearing potential) 5. Known history of allergic reactions to tamsulosin or terazosin 6. Patient is concomitantly taking warfarin or H2 receptor blockers 7. Patients with clinical condition(s) judged by the researcher/ clinician to be unsuitable for participation in the study
💊

What it tests

  • Terazosin
  • Tamsulosin
📍

Where

2 sites
Sultanah Bahiyah Hospital, Alor Setar
Alor Star, Malaysia
Hospital Pulau Pinang
George Town, Malaysia
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy